Your browser doesn't support javascript.
loading
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock, Sophia; Übelhart, Rudolf; Schubert, Maria-Luisa; Fan, Fuli; He, Bailin; Hoffmann, Jean-Marc; Wang, Lei; Wang, Sanmei; Gong, Wenjie; Neuber, Brigitte; Hückelhoven-Krauss, Angela; Gern, Ulrike; Christ, Christiane; Hexel, Monika; Schmitt, Anita; Schmidt, Patrick; Krauss, Jürgen; Jäger, Dirk; Müller-Tidow, Carsten; Dreger, Peter; Schmitt, Michael; Sellner, Leopold.
Afiliación
  • Stock S; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Übelhart R; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Schubert ML; Clinical Cooperation Unit "Applied Tumor-Immunity", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Fan F; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • He B; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Hoffmann JM; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Wang L; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Wang S; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Gong W; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Neuber B; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Hückelhoven-Krauss A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Gern U; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Christ C; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Hexel M; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Schmitt A; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Schmidt P; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Krauss J; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Jäger D; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Müller-Tidow C; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Dreger P; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Schmitt M; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Sellner L; German Cancer Consortium (DKTK), Heidelberg, Germany.
Int J Cancer ; 145(5): 1312-1324, 2019 09 01.
Article en En | MEDLINE | ID: mdl-30737788
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Purinas / Receptores de Antígenos de Linfocitos T / Linfocitos T / Leucemia Linfocítica Crónica de Células B / Inmunoterapia Adoptiva / Quinazolinonas Tipo de estudio: Guideline Límite: Animals / Humans Idioma: En Revista: Int J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Purinas / Receptores de Antígenos de Linfocitos T / Linfocitos T / Leucemia Linfocítica Crónica de Células B / Inmunoterapia Adoptiva / Quinazolinonas Tipo de estudio: Guideline Límite: Animals / Humans Idioma: En Revista: Int J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Alemania